Results 171 to 180 of about 6,619,911 (229)

Anti-GBM disease in pregnancy. [PDF]

open access: yesBMJ Case Rep
Kafagi AH, Li AS, Jayne D, Brix SR.
europepmc   +1 more source

RBM12 Maintains Glioma Stem Cells by Activating Amino Acid‐Dependent mTORC1 Signaling via SLC7A5 mRNA Stabilization

open access: yesAdvanced Science, Volume 13, Issue 52, 18 September 2026.
This study shows that in glioma stem cells (GSCs), RBM12 recruits ALKBH5 to remove m6A from SLC7A5 transcripts, thereby enhancing mRNA stability, which elevates large neutral amino acid (LNAA) levels and activates mTORC1, promoting GSC proliferation, self‐renewal, and tumor growth.
Hong Lei   +18 more
wiley   +1 more source

Eye‐Brain Neuroimmune Axis Enables Long‐Term Survival in Glioblastoma by Modulating Brain Immune Surveillance and Neuronal Excitability

open access: yesAdvanced Science, Volume 13, Issue 52, 18 September 2026.
The eye–brain neuroimmune axis triggers immune activation and disrupts pathological neuronal connectivity to extend glioblastoma survival. ABSTRACT As an anatomical extension of the central nervous system (CNS), the eye harbors rich neural and immune interfaces with the brain. However, the integrated immunological and neurological nexus between the eye
Mingyue Cui   +9 more
wiley   +1 more source

Biodegradable Acoustic Targeting for Ultrasound‐Supported Gene Therapy (BATUS) in Glioblastoma

open access: yesAdvanced Science, Volume 13, Issue 53, 24 September 2026.
ABSTRACT Glioblastoma (GBM) remains one of the most challenging brain malignancies due to the restrictive nature of the blood–brain barrier (BBB), which severely limits effective drug and gene delivery. To overcome this, we introduce Biodegradable Acoustic Targeting for Ultrasound‐Supported Gene Therapy (BATUS), a modular platform that enables safe ...
Gulsah Erel‐Akbaba   +25 more
wiley   +1 more source

A case of relapsing anti-GBM disease secondary to alemtuzumab therapy. [PDF]

open access: yesCEN Case Rep
Leibowitz SM   +3 more
europepmc   +1 more source

Overcoming intranasal delivery barriers with ultrastable polyzwitterionic siRNA nanocages for enhanced glioblastoma therapy

open access: yesBMEMat, Volume 4, Issue 3, September 2026.
A ROS‐responsive, zwitterionic nanocage enables stable, intranasal siRNA delivery to glioblastoma, promoting deep tumor penetration via non‐degradative pathways and trigeminal nerve transport. This platform achieves durable gene silencing and tumor suppression, offering a non‐invasive, storage‐stable strategy for treating glioma and other neurological ...
Jingwen Xie   +12 more
wiley   +1 more source

Ultrasmall Fe‐curcumin immunomodulators reinvigorate CAR‐T cells to potentiate solid tumor immunotherapy by mitigating cell exhaustion and senescence

open access: yesBMEMat, Volume 4, Issue 3, September 2026.
This work discovered a novel research that ultrasmall Fe‐curcumin immunomodulators could reinvigorate CAR‐T cells to potentiate solid tumor immunotherapy by mitigating cell exhaustion and senescence. Abstract CAR‐T cell immunotherapy has achieved exciting success in hematologic malignancies, but the therapeutic efficacy is relatively limited in solid ...
Jiazhi Duan   +15 more
wiley   +1 more source

Clinical characteristics of anti-GBM disease with thrombotic microangiopathy: a case report and literature review. [PDF]

open access: yesCEN Case Rep
Nakamura Y   +10 more
europepmc   +1 more source

A case report of double negative anti-GBM disease. [PDF]

open access: yesOxf Med Case Reports, 2019
Kheiri B   +6 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy